With snowballing healthcare spending and the emergence of new modalities of treatments, discussions are heating up around revisiting the scope of health coverage on pharmaceuticals, with the Ministry of Finance (MOF) and payers advocating the mantra of “large risks with…
HOME > ACADEMIA
ACADEMIA
- JDS, JGS Publish 1st Guideline for Treatment of Diabetes in the Elderly
May 22, 2017
- PI/II Study Suggests Efficacy of Eisai’s Anti-Fractalkine Antibody for RA
April 25, 2017
- Gastric Cancer Guidelines Likely to Recommend Opdivo in 3rd Line Settings
April 24, 2017
- Hepatology Society to Release Updated Hep C Guidelines Soon, Reflecting Ximency Use
March 3, 2017
- NCC to Begin IIT for Pediatric ALL with Velcade Plus 5 Drugs
February 23, 2017
- AMED Drafts Japan’s First Manual for Treatment of Mitochondrial Diseases
February 20, 2017
- PCSK9 Inhibitors More Effective than Statins at Lowering LDL-C: New Atherosclerosis Prevention Guidelines
January 31, 2017
- Zonisamide Investigator-Led Trial for Dementia Symptoms to Begin in April
January 27, 2017
- OB-GYN Society Again Nudges Govt to Reinstate HPV Vaccine Recommendation
January 19, 2017
- Reinstate HPV Vaccine Recommendation ASAP: OB-GYN Society
December 28, 2016
- NIBIOHN Bioinformatics Specialist Hopeful About Use of AI in Building Drug Discovery Support System
December 19, 2016
- New Lung Cancer Guidelines to Give Keytruda Grade A Recommendation as First-Line Treatment
December 19, 2016
- Need for Resistance Testing a Factor in Selection of IFN-Free Therapies for Hep C: Hepatologist
November 22, 2016
- Draft Guidelines on Pneumonia Treatment Set Guides for Selecting Antibacterial Agents: Respiratory Society
November 7, 2016
- Cancer Society to Issue New Lung Cancer Treatment GL in December; Positioning of Anti-PD-1 Antibodies Will Be Focus of Interest
October 31, 2016
- Japan Lung Cancer Society Seeks Early 1st-Line Nod for Keytruda
October 26, 2016
- Saitama Medical Univ. Develops Jointly with Daiichi Sankyo New Antibody with Potential Application in Treatment of FOP
October 26, 2016
- 6 Drug Makers to Participate in “Drug Redirection Program” for Compounds in Development Limbo: Univ. of Tokyo’s Initiative
October 18, 2016
- Osteoporosis Experts Express “Shock” at Discontinuation of Development of Odanacatib
October 7, 2016
- Amendment to Personal Info Law Shouldn’t Stymie Epidemiology Studies: Doctors
September 27, 2016
ページ
As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In my home country of Australia, there is a famous candy called “Minties”. Minties has a long-running advertising campaign, presenting comical situations, with the caption, “It’s moments like these.” The phase has become part of the Aussie vernacular, meaning in…